Identification of lncRNAs via microarray analysis for predicting HER2-negative breast cancer response to neoadjuvant chemotherapy

Dengjie Ouyang, Juan Su, Peng Huang, Moyun Li, Qianying Li, Qitong Chen, Qiongyan Zou, Xueping Feng, Ke Qian, Lun Li, Wenjun Yi

1Department of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University, China; 2Department of General Surgery, Xiangya Hospital, Central South University, China; 3Institute of Medical Science, Xiangya Hospital, Central South University, China. *Equal contributors.

Received February 10, 2018; Accepted March 24, 2018; Epub May 1, 2018; Published May 15, 2018

Abstract: Mortality is high in patients with locally advanced HER2-negative breast cancer, especially those with residual tumor after neoadjuvant chemotherapy (NAC). Tissue-specific long non-coding RNAs (lncRNAs) are responsible for specific breast cancer subtypes. To identify the lncRNAs involved in residual cancer tissues (RCTs) and to evaluate their potential for predicting HER2-negative breast cancer response to NAC, we used three paired tissues to compare differences in gene expression between RCTs and remittent tissues (RTs) after NAC in human HER2-negative breast cancer. Subsequently, we detected expression of the top ten up-regulated and down-regulated lncRNAs in 11 paired tissues via quantitative RT-PCR analysis. Finally, we explored the potential function of these dysregulated lncRNAs through bioinformatics analysis. Our results indicate that 1348 mRNAs and 183 lncRNAs were differentially expressed in RCTs compared with RTs, and the expression levels of four novel lncRNAs (DSCAM-AS1, LINC01508, lnc-MGST1-2 and lnc-BTG2-2) were in agreement with the microarray analysis results. Furthermore, we found that the expression level of LINC01508 was significantly related to poor prognosis, suggesting that LINC01508 is a potential biomarker for predicting breast cancer response to NAC, which might be helpful in exploring potential diagnostic factors and therapeutic targets for chemo-resistant HER2-negative breast cancer.

Keywords: HER2-negative breast cancer, neoadjuvant chemotherapy, chemo-resistance, gene expression microarray, long non-coding RNAs/lncRNAs

Introduction

Breast cancer (BC) is the second leading cause of cancer mortality among women worldwide [1]. Based on global transcriptomic analysis, BC is subdivided into different molecular subtypes, including luminal A, luminal B, HER2-enriched, claudin-low, basal-like, and normal breast-like subtypes [2, 3]. Moreover, luminal B PC can be further classified as either HER2 positive or HER2 negative [4]. For HER2-negative BC, the therapeutic strategy is restricted to chemotherapy and endocrine therapy. However, some patients acquire chemo-resistance during chemotherapy, which leads to treatment failure and high mortality. Therefore, it is important to clarify the molecular mechanism of chemotherapy resistance in HER2-negative BC patients.

Neoadjuvant chemotherapy (NAC) is associated with rates of disease-free survival (DFS) and overall survival (OS) comparable to those for adjuvant (post-surgical) chemotherapy [5]. NAC is standard in locally advanced and operable BC because it is intended to shrink the tumor and improve the chance for breast-conserving surgery [6]. BC represents a highly heterogeneous disease due to its diverse clinical outcomes and biological behavior [7]. Pathological complete response (pCR) is the best predictor of patient outcome after NAC [6, 8, 9]. Clinical trials have found that different BC subtypes have different rates of pCR and that patients who show pCR have a different prognosis depending on subtype [10]. Many studies and clinical observations have demonstrated that the prognosis of the luminal subtype is better...
than that of HER2-positive or triple-negative BC (TNBC). However, Niikura et al. [11] have suggested that patients with luminal tumors have lower pCR rates than those with HER2-positive or triple-negative tumors. The differential response in a single BC tumor tissue may be caused by clinical heterogeneity, which is an inherent feature of breast tumors. In residual cancer tissues (RCTs), the shape and structure of some cancer cells are changed [12], and cells can develop drug resistance. Thus, we speculate that the heterogeneity of BC tumor tissues after NAC may lead to poor outcomes, and the residual tumor is a critical indicator of treatment failure.

Long non-coding RNAs (lncRNAs) are defined as RNA genes longer than 200 bp with no coding potential [13], and recent studies have shown that lncRNA gene silencing is involved in chromatin modification, transcriptional activation, and many other important biological process [14]. In studies of lncRNAs in BC, several well-known lncRNAs have been identified to regulate BC endocrinotherapy [15, 16], such as HOTAIR [15, 16], IncRNA-ARA [17] and IncRNA-PANDA [18]. However, there is little information reported about the link between systematic expression of lncRNAs and HER2-negative BC.

In this study, we performed microarray analysis to establish an mRNA and IncRNA gene expression profile to identify genes that are differentially expressed between RCTs and remittent tissues (RTs) of HER2-negative BC after NAC. We also performed lab experiments and bioinformatics analysis to analyze the biological functions of the genes to identify mRNAs or lncRNAs that play important roles in chemo-resistance, with the goal of providing new targets for chemo-resistance studies of HER2-negative BC.

Materials and methods

Tissue collection

In this study, we recruited 48 BC patients who had undergone NAC, from which 34 patients were excluded according to our inclusion criteria, which is presented in Figure 1. BC tissue samples consisting of RCTs and RTs from patients who had invasive BC diagnosed histopathologically and had been treated with NAC were collected consecutively between September 2015 and May 2016. None of these patients accepted radiotherapy or endocrine therapy prior to breast tumor resection. The RTs were resected 2 mm from the edge of the tumor (according to the standard of safe cutting for breast-conserving surgery after NAC [19]). This study and the necessary sample collection were approved by the Ethical Review Committee of the Second Xiangya Hospital of Central South University.
RNA extraction and quality control

To isolate total RNA from each tissue, frozen tissues were resuspended in TRIzol reagent (Life Technologies) and were finally eluted into 100 μL of Elution Solution according to the manufacturer’s instructions. Quantification and quality checks were performed with a NanoDrop ND-2000 spectrophotometer (Thermo Scientific). All the RNA samples were stored at -80°C until further analysis.

LncRNA and mRNA microarray expression profiling

An Agilent Human Gene Expression (8*60 K, Design ID: 039494) microarray was used in this study. The IncRNAs were obtained from authoritative databases (i.e., RefSeq, Ensembl, UCSC Known genes, and LNCipedia) and related literature. The mRNAs were collected from RefSeq and GENCODE. Each transcript was represented by a specific exon or splice junction probe, which could identify individual transcripts accurately. Sample labeling, microarray hybridization, and washing were performed based on the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). Briefly, total RNA was transcribed to double-stranded cDNA, synthesized into cRNA and labeled with cyanine-3-CTP. Labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned with an Agilent Scanner G2505C (Agilent Technologies) and microarray profiling was conducted in the laboratory of the OE Biotechnology Company in Shanghai, People’s Republic of China.

Microarray results analysis and prediction of the functions of IncRNAs

Differential mRNA and IncRNA expression level based on microarray analysis: Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze the array images to obtain the raw data. GeneSpring (version 13.1, Agilent Technologies) was employed to complete the basic analysis of the raw data. Differentially expressed genes were then identified through the observed fold change (FC), and P values were calculated with a t-test. The threshold set for up- and down-regulated genes was an FC≥2.0 and a P value ≤0.05.

Co-expression of IncRNAs with mRNAs and function prediction: The gene ontology (GO) project provides a controlled vocabulary to describe gene and gene product attributes (http://www.geneontology.org) and has been widely used in large-scale genomic and transcriptional data functional studies. KEGG pathway analysis offered us a reliable method to elucidate the candidate biological pathways in which the IncRNAs interacted with the mRNAs. In this study, a bioinformatics analysis was performed to annotate the functional roles of the mRNAs, which were significantly correlated with the aforementioned IncRNAs.

qRT-PCR validation of 3 differentially expressed IncRNAs

Quantitative real-time PCR was performed to validate the microarray experiments using an independent cohort of 11 paired BC RCT and RT samples. Total RNA was extracted following the manufacturer’s protocols for each kit. RNA quality was confirmed using a NanoDrop 1000 spectrophotometer. An OD260/280 of approxi-
Chemoresistance IncRNAs of HER2-negative breast cancer

Int J Clin Exp Pathol 2018;11(5):2621-2628

Reverse transcription was performed by following the manufacturer’s protocols for a First Strand cDNA Synthesis Kit. The relative levels of the top ten up-regulated and down-regulated IncRNAs were determined via quantitative real-time PCR, which was performed using ABI Power SYBR1Green PCR Master Mix (Applied Biosystems, USA). Relative IncRNA expression levels were calculated using the 2-ΔΔCt method and were normalized to β-actin expression.

Kaplan-Meier analysis

The prognostic value of IncRNA expression was evaluated using the online database Kaplan-Meier Plotter (www.kmplot.com), which contained IncRNA expression data and survival information for 761 clinical BC patients. To analyze the relapse-free survival (RFS) of patients with BC, patient samples were split into two groups by median expression (high vs. low expression) and assessed using a Kaplan-Meier survival curve, with a hazard ratio (HR) with 95% confidence intervals (CI) and a log-rank P value.

Results

General expression profiles of differentially expressed IncRNAs and mRNAs

Feature Extraction software was used to obtain standardized data (Table 1). In unsupervised hierarchical clustering analysis, the differentially expressed IncRNAs were used to generate a heat map (Figure 2A). In total, 1801 genes were significantly altered (FC>2; P<0.05) in 3 pairs of samples, including 1348 mRNAs, 183 IncRNAs and 270 other genes (Figure 2B). The chromosome location data showed the number of up- or down-regulated IncRNAs located on specific human chromosomes (Figure 2C).
LncRNA function prediction

Hundreds of lncRNAs were co-expressed with thousands of mRNAs. The lncRNAs were clustered into hundreds of GO and KEGG pathway annotations, and the top ten GO biological processes and KEGG pathways enriched for the up-regulated or down-regulated lncRNAs are presented in Figure 3. In our results, “positive regulation of cell proliferation” was enriched in GO biological process for down-regulated lncRNAs, while “drug metabolism-cytochrome P450” was enriched in the KEGG pathway for down-regulated lncRNAs, which indicates the
Chemoresistance IncRNAs of HER2-negative breast cancer

possibility that the down-regulated IncRNAs participate in the chemo-resistance process.

RT-PCR confirmation and prognostic value

To validate the microarray data, the top ten up-regulated and down-regulated IncRNAs were examined by RT-PCR in 11 pairs of BC tissues (RCT and paired RT). In our results, we found that the expression of two up-regulated IncRNAs (LINC01508 and DSCAM-AS1) and two down-regulated IncRNAs (Inc-MGST1-2 and Inc-BTG2-2) was consistent with the microarray analysis and showed a significant difference between RCT and RT (Figure 4A).

We also predicted the prognostic value of IncRNA expression using Kaplan-Meier Plotter, and the clinical data co-related to 11 IncRNAs (6 up-regulated IncRNAs and 5 down-regulated IncRNAs) was acquired from TCGA database (The Cancer Genome Atlas). Interestingly, we found that the expression level of the novel IncRNA LINC01508 was significantly related to the overall survival of BC patients (P=0.014), and a high LINC01508 expression level indicated a poor BC patient prognosis (Figure 4B).

Discussion

BC is the most frequently diagnosed cancer in females, and a large number of patients, especially those with HER2-negative BC, experience treatment failure due to recurrence and metastasis. Various drugs have been approved for BC, but the acquisition of resistance remains a substantial obstacle for clinical management of the disease. After chemotherapy, the morphology and structure of some cancer cells are altered in RCTs. These tissues are characterized by degeneration of cancer cells, proliferation of fibrous tissue cells and infiltration of lymphocytes [12]. Additionally, epithelium- and cancer stem cell-related markers have been found in RCTs [20]. At the same time, drug resistance is enhanced in residual cancer cells. The resistant and normal stem cells exhibit the same pattern of accumulated mutations, which leads to newly acquired drug resistance via gene activation, point mutations and gene amplification [21]. However, the specific mechanism is unclear. Therefore, elucidation of these molecular mechanisms, particularly the mechanism associated with chemotherapy resistance, is crucial for better prediction of BC patient outcome and response to therapy.

Although study of IncRNAs has increased rapidly, only a few IncRNAs are well understood. Among the 183 differentially expressed IncRNAs we identified from the microarray results, only four were verified to be dysregulated in chemo-resistant tissues. Expression of IncRNAs exhibits temporal-spatial specificity. For instance, different IncRNAs derived from different types of tumor tissues and specific tissue-based IncRNAs are responsible for specific subtypes of BC. Therefore, determining how to design different groups for analysis is critical for identifying the subset-specific IncRNAs. This study is the first to perform a microarray analysis comparing RCTs and RTs, and the majority of the differentially expressed IncRNAs we found have seldom been reported previously.

The new IncRNAs are generally less evolutionarily conserved than known IncRNAs, with a large fraction unique to humans or primates. Our predicted function results showed enrichment in hundreds of biological processes and pathways, among which we found some cancer behaviors that were specifically enriched in the down-regulated IncRNA group, indicating that chemo-resistance is related to silencing of tumor suppressor genes. Through analysis of RNA-seq samples in a cohort of 947 BC patients, Yashar et al. [22] found that DSCAM-AS1 was down-regulated in BC tissues and participated in tumor progression and tamoxifen resistance.

Although the present results provided obvious evidence of some novel IncRNAs that may serve as BC biomarkers of poor survival, such as LINC01508, whose overexpression in BC tissues was related to poor clinical outcomes based on comparison of the Kaplan-Meier plots, further research should be performed in the future to verify our results. Particularly, it is difficult to obtain information regarding the location of the novel IncRNAs and the specific mechanisms underlying the process of BC cell proliferation, invasion, metastasis. In addition, we plan to use in vivo and in vitro experiments to further study the specific role of the differentially expressed genes in HER2-negative BC in chemo-resistance mechanisms.
Acknowledgements

This work was supported by the National Natural Science Foundation of China (81441084), the Natural Science Foundation of Hunan Province of China (2015jj4059), the Development and Reform Commission of Hunan Province of China (2014465), and the Hunan Provincial Innovation Foundation for Postgraduate (No. CX2017B073).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Wenjun Yi, Department of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha 410008, China. E-mail: yiwenjun@csu.edu.cn

References


